Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

830 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Influence of study characteristics on harm estimates from randomised controlled trials in patients with inflammatory arthritis receiving biological or synthetic antirheumatic drugs: a meta-epidemiological study.
Berg JI, Nielsen SM, Malm E, Ioannidis JPA, Furst DE, Smolen JS, Taylor PC, Kristensen LE, Tarp S, Ellingsen T, Christensen R. Berg JI, et al. Among authors: smolen js. Ann Rheum Dis. 2024 Nov 8:ard-2024-226129. doi: 10.1136/ard-2024-226129. Online ahead of print. Ann Rheum Dis. 2024. PMID: 39521451 Free article.
Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47.
Smolen JS, Trefler J, Racewicz A, Jaworski J, Zielińska A, Krogulec M, Jeka S, Wojciechowski R, Kolossa K, Dudek A, Krajewska-Włodarczyk M, Hrycaj P, Klimiuk PA, Burmester GR, Kim S, Bae Y, Yang G, Jung Y, Hong J, Keystone E. Smolen JS, et al. RMD Open. 2024 Oct 18;10(4):e004514. doi: 10.1136/rmdopen-2024-004514. RMD Open. 2024. PMID: 39424404 Free PMC article. Clinical Trial.
Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis.
Smolen JS, Taylor PC, Tanaka Y, Takeuchi T, Hashimoto M, Cara C, Lauwerys B, Tilt N, Ufuktepe B, Xavier RM, Balsa A, Curtis JR, Mikuls TR, Weinblatt M. Smolen JS, et al. Rheumatology (Oxford). 2024 Nov 1;63(11):3015-3024. doi: 10.1093/rheumatology/keae435. Rheumatology (Oxford). 2024. PMID: 39222436 Free PMC article. Clinical Trial.
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment.
Feist E, Fleischmann RM, Fatenejad S, Bukhanova D, Grishin S, Kuzkina S, Luggen M, Nasonov E, Samsonov M, Smolen JS. Feist E, et al. Among authors: smolen js. Ann Rheum Dis. 2024 Oct 21;83(11):1454-1464. doi: 10.1136/ard-2023-225473. Ann Rheum Dis. 2024. PMID: 38955475 Free PMC article. Clinical Trial.
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study.
Yu KS, Ryu H, Shin D, Park M, Hwang J, Moon SJ, Kim MG, Keystone E, Smolen JS, Kim S, Bae Y, Jeon D, Jang J, Yang G, Bae J, Lee J, Burmester GR. Yu KS, et al. Among authors: smolen js. Expert Opin Biol Ther. 2024 Jul;24(7):681-689. doi: 10.1080/14712598.2024.2321360. Epub 2024 Jun 21. Expert Opin Biol Ther. 2024. PMID: 38905143 Clinical Trial.
830 results